W/w HIV PrEP Rx — Yeztugo TRx were +2.0% w/w with 2.7% share; NRx were +2.3% w/w with 4.9% share. Descovy TRx were +0.0% w/w with 43.9% share, while Truvada, including generics, was +2.5% w/w with 48.9% share. Yeztugo repeat Rx mix was 10.4%, an aggregate Rx-based proxy. See Figures 6–11. 24 Jul 2026 08:24:52 ET │ 14 pages Vi e w p o i n t | US Biotechnology and Pharmaceuticals HIV Tracker: TRx, NRx and market share trends CITI'S TAKE The latest IQVIA data continue to show Gilead's leadership across the HIV ...